// App-Quantinova.ai

AB0204 (2021) : THE PROPER STUDY: INTERIM ANALYSIS OF A PAN-EU REAL-WORLD STUDY OF SB5 BIOSIMILAR FOLLOWING TRANSITION FROM REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS, OR PSORIATIC ARTHRITIS

Researchers

Presenter

  • U. Mller-Ladner

Principal Investigators

  • K. Gaffney

  • D. Jadon

  • U. Freudensprung

  • J. Addison

Medical Centers

  • Kerckhoff Klinik, Justus Liebig Universität Gießen, Abteilung für Rheumatologie und Klinische Immunologie, Bad Nauheim, Germany

  • NHS Foundation Trust, Norfolk and Norwich University Hospital, Norwich, United Kingdom

  • NHS Foundation Trust, Cambridge University Hospital, Cambridge, United Kingdom

  • Biogen GmbH, Medical Data Science and Analytics, Biosimilars, Baar, Switzerland

  • Biogen IDEC, Clinical Research, Biosimilars, Maidenhead, United Kingdom

Locations

  • Germany

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

  • Musculoskeletal

  • Gastroenterology (GU)

  • Infectious Diseases (ID)

Disease

  • Axial spondyloarthritis

  • Rheumatoid arthritis

  • Psoriatic arthritis

  • Ulcerative colitis

  • Spondyloarthritis

  • Crohn's disease

  • Inflammatory Arthritis

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • Observational

Phase

  • I

Study Id's

  • N/A

Sponsors

  • Biogen

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved